Three half-sandwich organometallic ruthenium(II) complexes containing purine analogs such as triazolopyrimidines of general formula [(η⁶-p-cym)Ru(L)Cl₂], where p-cym represents p-cymene and L is 5,6,7-trimethyl-1,2,4-triazolo[1,5-a]pyrimidine (tmtp for 1), 5,7-diethyl-1,2,4-triazolo[1,5-a]pyrimidine (detp for 2) and 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one (HmtpO for 3), have been synthesized and characterized by elemental analysis, infrared, multinuclear magnetic resonance spectroscopic techniques (¹H, ¹³C, ¹⁵N), and single-crystal X-ray diffraction (for 1 and 2). All these complexes have been thoroughly screened for their in vitro cytotoxicity against MCF-7 and HeLa cell lines as well as L929 murine fibroblast cells, indicating [(η⁶-p-cym)Ru(HmtpO)Cl₂] (3) as the most active representative against the HeLa cell line and simultaneously being 64-fold less toxic to normal L929 murine fibroblast cells than cisplatin. At the same time, 3 has shown antimetastatic activity comparable to NAMI-A against HeLa cells both after 24 and 48 h of treatment in a wound healing assay. In order to better understand the mechanism of anticancer action and differences in the cytotoxic activity of 1–3, the studies were expanded to determining their lipophilicity, the kinetic stability at pH 6.5–8, the effect on reactive oxygen species (ROS) production in HeLa cells and interactions with significant biomolecules (DNA and albumin) by using molecular docking and circular dichroism (CD) experiments. Furthermore, antiparasitic studies against L. braziliensis, L. infantum and T. cruzi reveal that the newly synthesized complexes 1–3 are very promising candidates which can compete with commercial antiparasitic drugs. Complex 3 in particular, on top of exhibiting a high antiparasitic effect (IC₅₀ < 1 μM against two strains), reaches a selectivity index >1000.

Three sawhorse-type ruthenium(I) complexes containing purine analogs such as triazolopyrimidines of general formula [Ru₂(CO)₄(μ-OOCCH₃)₂(L)₂], where L is 1,2,4-triazolo[1,5-a]pyrimidine (tp for 1), 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine (dbtp for 2) and 5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine (dptp for 3), have been synthesized and characterized by elemental analysis, infrared, multinuclear magnetic resonance spectroscopic techniques (¹H, ¹³C, ¹⁵N), and single-crystal X-ray diffraction (for 1 and 2). By assay with myoglobin, the photo-activated CO-releasing molecules (PhotoCORMs) character of (1-3) have been confirmed, thus indicating the possibility of use in CO-based therapies. The importance of UV-induced modification has been investigated in the context of anticancer properties. Complexes (1) and (2) have been thoroughly screened for their in vitro cytotoxicity against various cancer cell lines: MCF-7 (breast cancer), HeLa (cervical cancer) and C32 (melanoma), as well as L929 normal fibroblasts in the dark and presence of UV-A light (365 nm). The results were compared to cisplatin and two reference ruthenium complexes, namely NAMI-A and KP1019. The most hydrophilic [Ru₂(CO)₄(μ-OOCCH₃)₂(tp)₂] (1) (logP = -1.12) was found to be more cytotoxic than (2), despite lower cellular uptake measured by ICP-MS toward HeLa cells. Importantly, photo-induced stimulation of cells with (1) resulted in lower decrease in the viability of L929 normal cells (IC₅₀ = 154.7 ± 6.5 µM) in comparison with HeLa cancer cells (IC₅₀ = 66.7 ± 3.4 µM). Photo-induced stimulation of (1) and (2) increases ROS generation, and their anticancer activity may be a partially ROS-dependent phenomenon.

Two new Ag(I) complexes with 1,3-bis(imidazol-1-ylmethyl)benzene (L1) and 1,3-bis(imidazol-1-ylmethyl)-5-methylbenzene (L2), namely {[AgL1]CF₃SO₃}_n (1) and {[AgL2]CF₃SO₃}_n (2), were synthesised and characterised by SCXRD to uncover the effect that introducing a methyl group to the benzene core of the ligand has on the molecular/crystal structure of the metal complex. The studies revealed a high level of isostructurality of the formed Ag(I) complexes, consisting of 1D cationic chains with the charge neutralised by the counterions applied. These results triggered structural investigations of the parent ligands, which, as revealed by SCXRD, crystallise as dihydrates in different space groups of a monoclinic system. Further analyses revealed that the motifs in their molecular packing in general stay the same. However, some morphotropic/positional adjustments are taking place in L2 to accommodate the presence of the methyl substituent.

Herein we describe an alternative strategy to achieve the preparation of nanoscale Cu₃N. Copper(II) oxide/hydroxide nanopowder precursors were successfully fabricated by solution methods. Ammonolysis of the oxidic precursors can be achieved essentially pseudomorphically to produce either unsupported or supported nanoparticles of the nitride. Hence, Cu₃N particles with diverse morphologies were synthesized from oxygen-containing precursors in two-step processes combining solvothermal and solid−gas ammonolysis stages. The single-phase hydroxochloride precursor, Cu₂(OH)₃Cl was prepared by solution-state synthesis from CuCl₂·2H₂O and urea, crystallising with the atacamite structure. Alternative precursors, CuO and Cu(OH)₂, were obtained after subsequent treatment of Cu₂(OH)₃Cl with NaOH solution. Cu₃N, in the form of micro- and nanorods, was the sole product formed from ammonolysis using either CuO or Cu(OH)₂. Conversely, the ammonolysis of dicopper trihydroxide chloride resulted in two-phase mixtures of Cu₃N and the monoamine, Cu(NH₃)Cl under similar experimental conditions. Importantly, this pathway is applicable to afford composite materials by incorporating substrates or matrices that are resistant to ammoniation at relatively low temperatures (ca. 300 °C). We present preliminary evidence that Cu₃N/SiO₂ nanocomposites (up to ca. 5 wt.% Cu₃N supported on SiO₂) could be prepared from CuCl₂·2H₂O and urea starting materials following similar reaction steps. Evidence suggests that in this case Cu₃N nanoparticles are confined within the porous SiO₂ matrix.